Abstract
One hundred and thirty patients with active symptoms of Crohn's disease were treated in a double blind randomised controlled trial with rifampicin, isoniazid, and ethambutol, or identical placebos for up to two years. All other treatment considered necessary was continued. Analyses were based on 126 patients, 63 in each treatment group. Thirty seven in the active and 30 in the placebo group had previous surgical procedures. There was no difference in concomitant treatment between the two groups. Thirty in the active and 46 in the placebo groups were taking corticosteroids at entry to the trial. Forty eight of 63 patients in the active and 49 of 63 in the placebo group, completed at least 12 months' therapy. Reasons for early withdrawal included pregnancy, adverse reaction, and failure to comply.
There was no significant difference in the mean number of months completed between the two groups. Nineteen adverse reactions were recorded for 17 patients in the active group compared with three reactions in patients on placebo. All of the nine patients withdrawn early because of adverse reactions were in the active group. Fifteen patients on active treatment and 14 on placebo had surgery during the trial with no difference in the type of surgery required between the groups. Radiological assessments based on 98 patients at the end of the trial showed no significant differences between groups in changes of extent of disease. More patients developed strictures on placebo compared with active treatment but without a statistically significant difference.
No differences were found between groups for the total prednisolone dose or the number of days on which prednisolone dose was 10 mg or above. Serial measurements of body weight and Crohn's disease activity index (CDAI) together with blood values for albumin, haemoglobin, white cell count, and platelets showed no consistent differences between groups. There were occasional significant differences for some of these values between groups, which were not sustained. The Disease activity was assessed at each visit using the modified Harvey-Bradshaw Crohn's disease activity index -CDAI. 18 Because ethambutol has been associated with impaired visual acuity, which is heralded by impaired colour discrimination, measurements of this and visual acuity were made at the start of the trial and at six monthly intervals. All patients and their general practitioners were warned of possible side effects from ethambutol. An ophthalmologist was consulted about ocular problems before or during the trial period.
Patient compliance was assessed by an independent nurse using tablet counts and urine checks, at each clinic attendance; the orange discolouration of urine produced by rifampicin was recorded by the nurse but this information was withheld from doctors responsible for patient care. In practice this provided effective 'blinding'.
Early withdrawals occurred because of adverse drug effects, poor compliance, pregnancy or plans for pregnancy, or death. Patients who required surgery during the trial discontinued therapy for about two weeks and then recommenced with their usual dose for the remainder of the trial. If breaks in therapy occurred, the trial period was extended so that 24 months of treatment were given where possible. Because the length of follow up was commensurate with the duration of accrual no arrangements were made for an interim analysis, nor were 'stopping rules' constructed, but surgical intervention and early withdrawals were anticipated in a substantial number. Important points to indicate change in the clinical state were the Harvey-Bradshaw disease activity score, supplemented by changes in weight, platelet count, and serum albumin. Radiological features, or where appropriate endoscopy or surgical findings were the basis for change in extent of disease.
STATISTICAL METHODS
The sample size required to achieve adequate power was assessed when the study was planned. The primary objective was to discover if treatment had a favourable effect on the course of the disease over two years. The initial calculation, however, was based on a projected five year proportion remaining in remission of 10 per cent on standard management, increasing to one third on active treatment; a total of 120 patients yielded a power well above 0 8 at ct=0 05. It was estimated that a comparison based on a continuous outcome measure, CDAI at two years, using the baseline value as covariate, would be more powerful.
Comparisons between groups were made on an intention to treat basis as far as possible; withdrawal of active treatment did not In each group, 54 of 63 patients required prednisolone at some time during the trial period. No clear differences were found between the groups for total prednisolone dose or the number of days on which prednisolone dose was 10 mg or above (Fig 1) . Because the number of patients taking prednisolone was different in the two groups at entry to the trial, the disease activity was analysed incorporating prednisolone dose at entry as an additional covariate and results showed no quantitative difference between groups. Analysis ofCDAI showed a benefit in terms of abdominal pain, mass, and wellbeing for active treatment at two months, which was not sustained. Total scores ofdisease activity showed no significant differences (Fig 1/Table V ). We are very conscious of the considerable problems associated with clinical trials in Crohn's disease. Although patients were randomised, there were significantly more patients receiving prednisolone in the placebo group on entry to the trial. In theory this may have affected the outcome; the placebo group could have fared better because of the benefits of their prednisone, or conversely worse because they represented more severe disease. Thus a separate analysis of disease activity was made with the initial prednisolone dose as an additional covariate, but this showed no differences. The large variation in clinical features between individual patients makes it difficult to define a homogeneous group. It would also be unethical to discontinue other treatment thought to be necessary in patients with active disease over a prolonged period, and the effect of such treatment could mask any additional benefit from the 'trial drug' under investigation. The problem is further compounded by the unpredictable variations in disease activity that seem to occur irrespective of therapy in patients followed up over a long period.
Perhaps a more fundamental problem is related to the interpretation of results from trials ofanti-tuberculous therapy in Crohn's disease. If we begin with the proposition that a mycobacterium is the cause of this condition, improvement in symptoms after appropriate therapy does not necessarily support the proposition. Likewise, failure to improve with treatment does not exclude the possible role of mycobacteria initiating the disease. Symptoms in patients with Crohn's disease are a result of inflammation in the bowel wall and anatomical abnormalities that may develop, such as strictures, fistulas, and abscesses. Although anti-tuberculous chemo- There has been only one other controlled trial of anti-tuberculous drugs'6 in which 40 patients with severe active Crohn's disease were randomised to nine months' treatment with either ethambutol, rifampicin, dapsone, and clofazimine or placebo. All patients were given methylprednisolone for up to eight weeks before trial treatment to achieve remission. Sixty eight per cent of those receiving placebo and 17% receiving active treatment relapsed during the study.
There have also been a number of reports in which anti-mycobacterial treatment was found to be ineffective. In a double blind cross over trial25 14 The primary objective of this trial was to examine whether there was a net benefit for patients given anti-tuberculous chemotherapy. It could only be expected to answer 'whether' the treatment had such an effect rather than 'how'. The absence ofany apparent benefit, however, in these patients treated for up to 24 months, certainly fails to support the hypothesis that mycobacteria play an important part in the pathogenesis of this disease. Should subsequent follow up of the groups also fail to show any difference in disease recurrence, the hypothesis would be further weakened. 
